280 related articles for article (PubMed ID: 32901886)
1. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
2. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.
Järås M; Miller PG; Chu LP; Puram RV; Fink EC; Schneider RK; Al-Shahrour F; Peña P; Breyfogle LJ; Hartwell KA; McConkey ME; Cowley GS; Root DE; Kharas MG; Mullally A; Ebert BL
J Exp Med; 2014 Apr; 211(4):605-12. PubMed ID: 24616378
[TBL] [Abstract][Full Text] [Related]
3. Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells.
Park SM; Miyamoto DK; Han GYQ; Chan M; Curnutt NM; Tran NL; Velleca A; Kim JH; Schurer A; Chang K; Xu W; Kharas MG; Woo CM
Cancer Cell; 2023 Apr; 41(4):726-739.e11. PubMed ID: 36898380
[TBL] [Abstract][Full Text] [Related]
4. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.
Huart AS; MacLaine NJ; Meek DW; Hupp TR
J Biol Chem; 2009 Nov; 284(47):32384-94. PubMed ID: 19759023
[TBL] [Abstract][Full Text] [Related]
5. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
6. MDMX inhibits casein kinase 1α activity and stimulates Wnt signaling.
Huang Q; Chen L; Schonbrunn E; Chen J
EMBO J; 2020 Jul; 39(14):e104410. PubMed ID: 32511789
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
[TBL] [Abstract][Full Text] [Related]
8. Casein kinase 1α regulates an MDMX intramolecular interaction to stimulate p53 binding.
Wu S; Chen L; Becker A; Schonbrunn E; Chen J
Mol Cell Biol; 2012 Dec; 32(23):4821-32. PubMed ID: 23028042
[TBL] [Abstract][Full Text] [Related]
9. Exploiting the MDM2-CK1α protein-protein interface to develop novel biologics that induce UBL-kinase-modification and inhibit cell growth.
Huart AS; MacLaine NJ; Narayan V; Hupp TR
PLoS One; 2012; 7(8):e43391. PubMed ID: 22916255
[TBL] [Abstract][Full Text] [Related]
10. Tumor-derived CK1α mutations enhance MDMX inhibition of p53.
Liu X; Huang Q; Chen L; Zhang H; Schonbrunn E; Chen J
Oncogene; 2020 Jan; 39(1):176-186. PubMed ID: 31462704
[TBL] [Abstract][Full Text] [Related]
11. Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma.
Liu G; Li H; Zhang W; Yu J; Zhang X; Wu R; Niu M; Liu X; Yu R
J Cell Mol Med; 2021 Aug; 25(15):7395-7406. PubMed ID: 34216174
[TBL] [Abstract][Full Text] [Related]
12. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML.
Kojima K; Shimanuki M; Shikami M; Samudio IJ; Ruvolo V; Corn P; Hanaoka N; Konopleva M; Andreeff M; Nakakuma H
Leukemia; 2008 Sep; 22(9):1728-36. PubMed ID: 18548093
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of XIAP and autophagy induces apoptosis and differentiation in acute myeloid leukaemia.
Huang Z; Zhou J; Jiang Y; Han Y; Wang X; Li F; Jiang S; Yu K; Zhang S
J Cell Mol Med; 2023 Jun; 27(12):1682-1696. PubMed ID: 37154878
[TBL] [Abstract][Full Text] [Related]
15. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
[TBL] [Abstract][Full Text] [Related]
16. Regulation of p53-MDMX interaction by casein kinase 1 alpha.
Chen L; Li C; Pan Y; Chen J
Mol Cell Biol; 2005 Aug; 25(15):6509-20. PubMed ID: 16024788
[TBL] [Abstract][Full Text] [Related]
17. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
18. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
19. Casein kinase 1α-dependent feedback loop controls autophagy in RAS-driven cancers.
Cheong JK; Zhang F; Chua PJ; Bay BH; Thorburn A; Virshup DM
J Clin Invest; 2015 Apr; 125(4):1401-18. PubMed ID: 25798617
[TBL] [Abstract][Full Text] [Related]
20. ULK1 inhibition as a targeted therapeutic strategy for FLT3-ITD-mutated acute myeloid leukemia.
Hwang DY; Eom JI; Jang JE; Jeung HK; Chung H; Kim JS; Cheong JW; Min YH
J Exp Clin Cancer Res; 2020 May; 39(1):85. PubMed ID: 32393312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
